Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 311

1.

Preoperative weight loss: is waiting longer before bariatric surgery more effective?

Eng V, Garcia L, Khoury H, Morton J, Azagury D.

Surg Obes Relat Dis. 2019 Mar 20. pii: S1550-7289(19)30066-8. doi: 10.1016/j.soard.2019.03.012. [Epub ahead of print]

PMID:
31104959
2.

Readmissions Following Isolated Coronary Artery Bypass Graft Surgery in the United States (from the Nationwide Readmissions Database 2010 to 2014).

Khoury H, Sanaiha Y, Rudasill SE, Mardock AL, Sareh S, Benharash P.

Am J Cardiol. 2019 Apr 23. pii: S0002-9149(19)30457-6. doi: 10.1016/j.amjcard.2019.04.018. [Epub ahead of print]

PMID:
31104778
3.

Trends in mortality, readmissions, and complications after endovascular and open infrainguinal revascularization.

Khoury H, Morales RR, Sanaiha Y, Rudasill S, Jaman R, Gelabert H, Benharash P.

Surgery. 2019 May 6. pii: S0039-6060(19)30170-9. doi: 10.1016/j.surg.2019.03.019. [Epub ahead of print]

PMID:
31072666
4.

REDUCTION OF STAFF RADIATION DOSE IN PROSTATIC ARTERY EMBOLISATION.

Andrade G, Garzón WJ, Khoury HJ, Savignon J, de Barros VSM, Fernandes JL, Abud DG.

Radiat Prot Dosimetry. 2019 Apr 29. pii: ncz121. doi: 10.1093/rpd/ncz121. [Epub ahead of print]

PMID:
31034554
5.

Association of preoperative systemic corticosteroid therapy with surgical outcomes in chronic obstructive pulmonary disease patients.

Arbid SA, El-Khoury H, Jamali F, Tamim H, Chami H.

Ann Thorac Med. 2019 Apr-Jun;14(2):141-147. doi: 10.4103/atm.ATM_245_18.

6.

Evaluation of the MOSkin dosimeter for diagnostic X-ray CT beams.

Mendes Pereira L, Khoury HJ, Andrade MEA, Barros VSM, Cutajar D, Rosenfeld AB.

Phys Med. 2019 Apr;60:150-155. doi: 10.1016/j.ejmp.2019.03.030. Epub 2019 Apr 5.

PMID:
31000076
7.

Association of Autoimmune Connective Tissue Disease and Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation.

Rudasill SE, Sanaiha Y, Xing H, Mardock AL, Khoury H, Jaman R, Ebrahimi R, Benharash P.

Am J Cardiol. 2019 May 15;123(10):1675-1680. doi: 10.1016/j.amjcard.2019.02.023. Epub 2019 Feb 22.

PMID:
30850212
8.

Pretransplant malignancy among lung transplant recipients in the modern era.

Rudasill SE, Iyengar A, Sanaiha Y, Khoury H, Mardock AL, Xing H, Kwon MH, Hunter C, Benharash P.

Surgery. 2019 Feb 28. pii: S0039-6060(19)30039-X. doi: 10.1016/j.surg.2019.01.008. [Epub ahead of print]

PMID:
30827490
9.

Attenuated chromatin compartmentalization in meiosis and its maturation in sperm development.

Alavattam KG, Maezawa S, Sakashita A, Khoury H, Barski A, Kaplan N, Namekawa SH.

Nat Struct Mol Biol. 2019 Mar;26(3):175-184. doi: 10.1038/s41594-019-0189-y. Epub 2019 Feb 18.

PMID:
30778237
10.

Clinical Outcomes of Infective Endocarditis in Injection Drug Users.

Rudasill SE, Sanaiha Y, Mardock AL, Khoury H, Xing H, Antonios JW, McKinnell JA, Benharash P.

J Am Coll Cardiol. 2019 Feb 12;73(5):559-570. doi: 10.1016/j.jacc.2018.10.082.

PMID:
30732709
11.

Impact of Approach and Hospital Volume on Cardiovascular Complications After Pulmonary Lobectomy.

Sanaiha Y, Khoury H, Kavianpour B, Yazdani S, Gowland L, Iyengar A, Juo YY, Benharash P.

J Surg Res. 2019 Mar;235:202-209. doi: 10.1016/j.jss.2018.09.062. Epub 2018 Oct 30.

PMID:
30691795
12.

RADIATION DOSES TO ANAESTHETISTS DURING PROSTATIC ARTERY EMBOLIZATION INTERVENTIONAL PROCEDURES.

Garzón WJ, Khoury HJ.

Radiat Prot Dosimetry. 2019 Jan 21. doi: 10.1093/rpd/ncy295. [Epub ahead of print]

PMID:
30668847
13.

Safety and survival outcomes for bloodless transplantation in patients with myeloma.

Joseph NS, Kaufman JL, Boise LH, Valla K, Almaula DK, Obidike CO, Langston AA, Waller EK, Khoury HJ, Flowers CR, Graiser M, Heffner LT, Lonial S, Nooka AK.

Cancer. 2019 Jan 15;125(2):185-193. doi: 10.1002/cncr.31677. Epub 2018 Nov 27. Review.

PMID:
30480777
14.

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W.

Blood Adv. 2018 Nov 13;2(21):2922-2936. doi: 10.1182/bloodadvances.2018024844.

15.

Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.

Khoury H, He R, Schimmer A, Beadle JR, Hostetler KY, Minden MD.

Chemotherapy. 2018;63(4):225-237. doi: 10.1159/000491705. Epub 2018 Oct 29.

PMID:
30372692
16.

PERFORMANCE OF THE INSTADOSETM DOSEMETER FOR INTERVENTIONAL RADIOLOGY AND CARDIOLOGY APPLICATION.

Garzón WJ, Khoury H, Ovalle SAM, Medeiros RB.

Radiat Prot Dosimetry. 2018 Oct 1. doi: 10.1093/rpd/ncy172. [Epub ahead of print]

PMID:
30272212
17.

The performance of a multi guard ring (MGR) diode for clinical electron beams dosimetry.

Nascimento CR, Asfora VK, Gonçalves JAC, Khoury HJ, Barros VSM, Kalil LF, Bueno CC.

Appl Radiat Isot. 2018 Nov;141:112-117. doi: 10.1016/j.apradiso.2018.07.002. Epub 2018 Jul 3.

PMID:
30212784
18.

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.

Ottmann O, Saglio G, Apperley JF, Arthur C, Bullorsky E, Charbonnier A, Dipersio JF, Kantarjian H, Khoury HJ, Kim DW, Healey D, Strauss L, Cortes JE.

Blood Cancer J. 2018 Sep 3;8(9):88. doi: 10.1038/s41408-018-0122-3. No abstract available.

19.

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated.

Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C; GV12-02 Writing Committee on behalf of the CIBMTR® Graft-versus-Host Disease Working Committee.

Haematologica. 2018 Oct;103(10):1708-1719. doi: 10.3324/haematol.2017.182550. Epub 2018 Aug 3.

20.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.

Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf TH, Khoury HJ.

Haematologica. 2018 Aug;103(8):1298-1307. doi: 10.3324/haematol.2017.171249. Epub 2018 May 17.

21.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.

22.

A Large Stone Within a Ureteroceles: A Diagnostic Pitfall and the Utility of Holmium Laser Deroofing as a Viable Surgical Option.

El-Khoury HJ, Aw HC, Gilbourd D, Liu MI.

J Endourol Case Rep. 2018 Feb 1;4(1):18-20. doi: 10.1089/cren.2017.0139. eCollection 2018.

23.

Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O.

Leuk Res. 2018 Apr;67:67-74. doi: 10.1016/j.leukres.2018.02.008. Epub 2018 Feb 14. Review.

PMID:
29466766
24.

Management of an enormous inferior mesenteric vein aneurysm.

Guirgis M, El-Khoury H, Sieunarine K.

J Vasc Surg Venous Lymphat Disord. 2018 Mar;6(2):241-243. doi: 10.1016/j.jvsv.2017.11.002.

PMID:
29454439
25.

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Khoury HJ, Gambacorti-Passerini C, Brümmendorf TH.

Ann Oncol. 2018 Mar 1;29(3):578-587. doi: 10.1093/annonc/mdy019. Review.

26.

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.

Khoury HJ, Langston AA, Kota VK, Wilkinson JA, Pusic I, Jillella A, Bauer S, Kim AS, Roberts D, Al-Kadhimi Z, Bodo I, Winton E, Arellano M, DiPersio JF.

Bone Marrow Transplant. 2018 Jul;53(7):826-831. doi: 10.1038/s41409-017-0081-5. Epub 2018 Jan 24.

27.

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Hosoba S, Waller EK, Shenvi N, Graiser M, Easley KA, Al-Kadhimi Z, Andoh A, Antun AG, Barclay S, Josephson CD, Koff JL, Khoury HJ, Langston AA, Zimring JC, Roback JD, Giver CR.

Biol Blood Marrow Transplant. 2018 May;24(5):973-982. doi: 10.1016/j.bbmt.2018.01.003. Epub 2018 Jan 4.

28.

Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.

Bejanyan N, Zhang MJ, Wang HL, Lazaryan A, de Lima M, Marks DI, Sandmaier BM, Bachanova V, Rowe J, Tallman M, Kebriaei P, Kharfan-Dabaja M, Peter Gale R, Lazarus HM, Ustun C, Copelan E, Ky Hamilton B, Schiller G, Hogan W, Hashmi S, Seftel M, Kanakry CG, Olsson RF, Martino R, Saber W, Khoury HJ, Weisdorf DJ.

Biol Blood Marrow Transplant. 2018 May;24(5):945-955. doi: 10.1016/j.bbmt.2017.12.784. Epub 2017 Dec 21.

29.

Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States.

Wagner M, Samaha D, Khoury H, O'Neil WM, Lavoie L, Bennetts L, Badgley D, Gabriel S, Berthon A, Dolan J, Kulke MH, Goetghebeur M.

Adv Ther. 2018 Jan;35(1):81-99. doi: 10.1007/s12325-017-0653-1. Epub 2017 Dec 21.

30.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR.

Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733. doi: 10.1016/j.bbmt.2017.11.025. Epub 2017 Dec 25.

31.

Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.

Jillella AP, Arellano ML, Heffner LT, Gaddh M, Langston AA, Khoury HJ, Mangoankar A, Kota VK.

Hematol Rep. 2017 Sep 26;9(3):7083. doi: 10.4081/hr.2017.7083. eCollection 2017 Sep 26. No abstract available.

32.

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective Switch From Second-Generation Tyrosine Kinase Inhibitor to Imatinib.

Kota VK, Kong JH, Arellano M, El Rassi F, Gaddh M, Heffner LT, Winton EF, Jillella AP, McLemore ML, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e71-e73. doi: 10.1016/j.clml.2017.09.004. Epub 2017 Sep 19.

PMID:
29032022
33.

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ.

Am J Hematol. 2017 Nov;92(11):1214-1223. doi: 10.1002/ajh.24887. Epub 2017 Sep 25.

34.

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.

Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Brümmendorf TH, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):684-695.e6. doi: 10.1016/j.clml.2017.06.001. Epub 2017 Jun 17.

35.

The safety of Bosutinib for the treatment of chronic myeloid leukemia.

Kong JH, Khoury HJ, Kim AS, Hill BG, Kota V.

Expert Opin Drug Saf. 2017 Oct;16(10):1203-1209. doi: 10.1080/14740338.2017.1363176. Epub 2017 Sep 5. Review.

PMID:
28774214
36.

Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017.

Khoury HJ, Williams LA, Atallah E, Hehlmann R.

Am Soc Clin Oncol Educ Book. 2017;37:468-479. doi: 10.14694/EDBK_175712.

37.

HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.

Zhao L, Fan J, Xia S, Pan Y, Liu S, Qian G, Qian Z, Kang HB, Arbiser JL, Pollack BP, Kudchadkar RR, Lawson DH, Rossi M, Abdel-Wahab O, Merghoub T, Khoury HJ, Khuri FR, Boise LH, Lonial S, Chen F, Chen J, Lin R.

J Biol Chem. 2017 Jun 16;292(24):10142-10152. doi: 10.1074/jbc.M117.788778. Epub 2017 May 3.

38.

Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.

Segal E, Martens M, Wang HL, Brazauskas R, Weisdorf D, Sandmaier BM, Khoury HJ, de Lima M, Saber W.

Cancer. 2017 Sep 1;123(17):3346-3355. doi: 10.1002/cncr.30737. Epub 2017 Apr 27.

39.

DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.

Gilabert-Perramon A, Torrent-Farnell J, Catalan A, Prat A, Fontanet M, Puig-Peiró R, Merino-Montero S, Khoury H, Goetghebeur MM, Badia X.

Int J Technol Assess Health Care. 2017 Jan;33(1):111-120. doi: 10.1017/S0266462317000149. Epub 2017 Apr 24.

PMID:
28434413
40.

Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA.

Wagner M, Khoury H, Bennetts L, Berto P, Ehreth J, Badia X, Goetghebeur M.

BMC Cancer. 2017 Apr 17;17(1):272. doi: 10.1186/s12885-017-3258-9.

41.

Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.

Khoury HJ, Collins RH Jr, Blum W, Stiff PS, Elias L, Lebkowski JS, Reddy A, Nishimoto KP, Sen D, Wirth ED 3rd, Case CC, DiPersio JF.

Cancer. 2017 Aug 15;123(16):3061-3072. doi: 10.1002/cncr.30696. Epub 2017 Apr 14.

42.

Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.

Guo X, Koff JL, Moffitt AB, Cinar M, Ramachandiran S, Chen Z, Switchenko JM, Mosunjac M, Neill SG, Mann KP, Bagirov M, Du Y, Natkunam Y, Khoury HJ, Rossi MR, Harris W, Flowers CR, Lossos IS, Boise LH, Dave SS, Kowalski J, Bernal-Mizrachi L.

Oncogene. 2017 Jul 20;36(29):4224-4232. doi: 10.1038/onc.2017.90. Epub 2017 Apr 3.

PMID:
28368397
43.

Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study.

Shah NN, McClellan W, Flowers CR, Lonial S, Khoury H, Waller EK, Langston A, Nooka AK.

Infect Control Hosp Epidemiol. 2017 Jun;38(6):651-657. doi: 10.1017/ice.2017.12. Epub 2017 Mar 23.

PMID:
28330512
44.

Buttressing of the EEA stapler during gastrojejunal anastomosis decreases rate of bleeding-related complications for laparoscopic gastric bypass.

Ichter ZA, Voeller L, Rivas H, Khoury H, Azagury D, Morton JM.

Surg Obes Relat Dis. 2017 May;13(5):802-806. doi: 10.1016/j.soard.2017.01.019. Epub 2017 Jan 11.

PMID:
28325504
45.

Improved survival after acute graft-versus-host disease diagnosis in the modern era.

Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J.

Haematologica. 2017 May;102(5):958-966. doi: 10.3324/haematol.2016.156356. Epub 2017 Mar 16.

46.

Radiation Exposure of Patients and Interventional Radiologists during Prostatic Artery Embolization: A Prospective Single-Operator Study.

Andrade G, Khoury HJ, Garzón WJ, Dubourcq F, Bredow MF, Monsignore LM, Abud DG.

J Vasc Interv Radiol. 2017 Apr;28(4):517-521. doi: 10.1016/j.jvir.2017.01.005. Epub 2017 Mar 2.

PMID:
28259503
47.

Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?

Kong JH, Winton EF, Heffner LT, Chen Z, Langston AA, Hill B, Arellano M, El-Rassi F, Kim A, Jillella A, Kota VK, Bodó I, Khoury HJ.

Cancer. 2017 Jul 1;123(13):2482-2488. doi: 10.1002/cncr.30608. Epub 2017 Feb 27.

48.

Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.

Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W; Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research, aresearch collaboration between the National Marrow Donor Program/Be the Match Registry and theMedicalCollegeofWisconsin.

Cancer. 2017 Jun 1;123(11):2035-2042. doi: 10.1002/cncr.30567. Epub 2017 Jan 24.

49.

Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.

Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, Mielcarek M, Rezvani A, Stockerl-Goldstein K, Khoury HJ, De Lima M, Saber W, Sandmaier B, Zhang MJ, Eapen M.

Cancer. 2017 Jun 1;123(11):2025-2034. doi: 10.1002/cncr.30536. Epub 2017 Jan 24.

50.

Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.

Xia S, Lin R, Jin L, Zhao L, Kang HB, Pan Y, Liu S, Qian G, Qian Z, Konstantakou E, Zhang B, Dong JT, Chung YR, Abdel-Wahab O, Merghoub T, Zhou L, Kudchadkar RR, Lawson DH, Khoury HJ, Khuri FR, Boise LH, Lonial S, Lee BH, Pollack BP, Arbiser JL, Fan J, Lei QY, Chen J.

Cell Metab. 2017 Feb 7;25(2):358-373. doi: 10.1016/j.cmet.2016.12.010. Epub 2017 Jan 12.

Supplemental Content

Loading ...
Support Center